Coordinated by GU Ventures
SciLifeLab DDD and New Modality Support in partnership to enhance support and funding possibilities for academic innovations
SciLifeLab Drug Discovery and Development (DDD) and New Modality Support (NMS) are establishing a strategic partnership to facilitate further development and improve access to funding for academic projects deriving from SciLifeLab DDD’s research program portfolio and wanting to develop into commercial phase.
SciLifeLab DDD platform offer industry-standard infrastructure within drug discovery to the Swedish academic research community, with the mission to support researchers to develop prototypes towards a preclinical proof-of-concept for new assets within small molecule, antibody, oligonucleotide and enabling technologies.
NMS’s role, with its network and expertise, is to facilitate the startup journey and enhance opportunities for projects to secure funding, investments, and partnerships. By providing support and guidance—especially in connecting with the right investors—NMS helps position startups for success.
”We support academic innovations through various modalities, and preclinical funding is vital when research projects exit our platform. The partnership with NMS further enables innovative Swedish scientific discoveries to be more successful in attracting capital”, says Kristian Sandberg, PhD, Assoc. Professor Co-Director for the Drug Discovery and Development (DDD) platform in Uppsala, SciLifeLab.
“The transition from academia to the startup journey is filled with hurdles and can be quite unforgiving. Early incorporation of strategies for research development, application, and commercialization is vital to increasing a project’s chances of attracting capital and achieving commercial success”, says Eduarde Rohner, PhD, NMS Lead and Business Development, GU Ventures in Gothenburg, which is one of the holding companies fully owned by the Swedish State and with the mission to commercialize research results.
“The latest advancements in research therapy are opening entirely new ways to treat severe diseases, emphasizing the need for increased preparedness for early-stage projects and the importance of support in unlocking Sweden’s innovative potential when it comes to commercial output,” says Klementina Österberg, CEO of GU Ventures.
For additional information, please contact:
Kristian Sandberg, kristian.sandberg@scilifelab.uu.se
Eduarde Rohner, eduarde.rohner@ventures.gu.se
About SciLifeLab DDD
The SciLifeLab Drug Discovery and Development (DDD) platform offers integrated drug discovery efforts to the Swedish academic research community. SciLifeLab DDD offer industry-standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept within small molecules, human antibodies, and new modality therapeutics.
For more information, please visit:
https://www.scilifelab.se/units/ddd-platform/
About New Modality Support (NMS)
NMS supports the further development and commercialization of individual research projects, primarily within the therapeutic oligonucleotide and ATMP sectors. By combining the experience and resources of participating parties with new, sector-specific expertise, value-creating services can be developed and deployed more efficiently. GU Ventures runs NMS and its partners are CCRM Nordic, OligoNova, Sahlgrenska Academy at the University of Gothenburg, and the Sahlgrenska University Hospital.
NMS is located at GoCo Health Innovation City in Mölndal and is supported by both the Västra Götaland Region through the Environment and Regional Development Board, as well as by the University of Gothenburg and GU Ventures. This support enables GU Ventures, the coordinator for NMS, to work strategically and sustainably towards the project´s success.
For more information, please visit:
